Veronica Hood, PhD

Dr. Hood joined the DSF staff in 2020. She has an MS in Biology from East Tennessee State University and a PhD in Cell, Stem Cell, and Developmental Biology from the University of Colorado. She spent 10 years in laboratory settings researching how small changes in genetic and molecular regulation contribute to complex neurological diseases. In 2007, Veronica had a son, Gabriel, who faced severe developmental challenges. Gabriel presented with initial seizure activity within his first two months of life, and his medical needs quickly became quite complex. Despite endless testing, a diagnosis remained elusive, and at the age of 8, Gabriel passed away. These experiences fueled Veronica’s passion to advance medical research and shaped her desire to support other families facing similar challenges. She hopes to apply her scientific knowledge and her understanding of the caregiver experience to support the Dravet community by facilitating Dravet-focused research and acting as a liaison between researchers, professionals, and families.

Veronica Hood PhD DSF Scientific Director

DSF-Funded Clinico-Genomics Research Study Now Recruiting for Remote Participants

At the end of 2023, DSF announced our largest-ever grant award in the amount of $1 million directed to Ingo Helbig, MD and Ethan Goldberg, MD, PhD at The Children’s Hospital of Philadlephia (CHOP) to lead a large study aiming to collect samples from 500 patients with SCN1A-related epilepsy for whole genome sequencing. This genetic […]

DSF-Funded Clinico-Genomics Research Study Now Recruiting for Remote Participants Read More »

Encoded Therapeutics begins enrolling first in-human trials for ETX101, a potential one-time, disease-modifying gene regulation therapy for SCN1A+ Dravet syndrome

2024 is proving to be a promising year for the advancement of targeted therapies for Dravet syndrome, including some newly enrolling clinical studies to investigate a novel genetic-based therapy from Encoded Therapeutics which we will discuss further in today’s blog post. Dravet syndrome is caused by mutations in one copy of the SCN1A gene, which

Encoded Therapeutics begins enrolling first in-human trials for ETX101, a potential one-time, disease-modifying gene regulation therapy for SCN1A+ Dravet syndrome Read More »

AI-Powered Progress: Transforming Epilepsy Care and Research with Technology

Artificial intelligence (AI) is the use of computer systems to perform complex tasks that would typically require a human to perform, such as visual perception, speech recognition, decision-making, translations, or even coming up with a title for this blog! The focus on AI continues to increase as the concept jumps out of the realm of

AI-Powered Progress: Transforming Epilepsy Care and Research with Technology Read More »

Updates on STK-001: A Possible Disease-Modifying Therapy for Dravet Syndrome

There have been some exciting data releases from Stoke Therapeutics regarding their Phase 1/2a trial for the investigational therapy, STK-001, that suggest this could be the first truly disease-modifying therapy for Dravet syndrome. Results indicate significant reductions in seizure frequency and notable improvements in measures related to behavior and cognition. In addition to a recent

Updates on STK-001: A Possible Disease-Modifying Therapy for Dravet Syndrome Read More »

Dravet Family Purple Banner

New Genetic Therapy for Dravet Syndrome Advances Towards Clinical Trials

Given the limited effectiveness of current therapies to treat Dravet syndrome and the significant burden of symptoms, much hope lies in the potential of targeted genetic therapies to treat Dravet syndrome at the root cause and modify the course of the disease. In the majority of cases, patients with Dravet syndrome carry mutations in the

New Genetic Therapy for Dravet Syndrome Advances Towards Clinical Trials Read More »

Dravet Family Purple Banner

Investigating PBA as a Treatment for Epilepsy

The pipeline for new therapies to address Dravet syndrome in 2024 is encouraging. There are several ongoing clinical trials for potential new treatments and even more in development. In today’s blog I will highlight a compound that is being investigated in a variety of human diseases and some recent work demonstrating there may be potential

Investigating PBA as a Treatment for Epilepsy Read More »

Dravet Family Purple Banner

2023 American Epilepsy Society Meeting Dravet-focused Recap

It is a continuing trend that research related to Dravet syndrome (DS) has robust representation at the annual American Epilepsy Society (AES) Meeting. DS came up across sessions large and small throughout the meeting, highlighting examples of the advancements in diagnosis, treatment algorithms, preclinical modeling, and novel genetic therapies that are occurring for DS. Notably,

2023 American Epilepsy Society Meeting Dravet-focused Recap Read More »

Scroll to Top
Skip to content